Kornimate/medical-research-clean huggingface dataset:
understanding neurocognitive impairment after trauma exposure

Conditions: Trauma, Psychological; Earthquake

Summary: individuals living in canterbury (new zealand) have experienced significant stress related to the canterbury earthquake sequence. previous research conducted at the department of psychological medicine (christchurch, new zealand) has shown significant cognitive difficulties in a group of cantabrians exposed to high levels of earthquake trauma. a high proportion (30%) perceive themselves to have significant cognitive difficulties, even seven years post-earthquake. people who perceive that they have cognitive difficulties find this distressing and tend to function less well in work and parenting. understanding pathways underlying cognitive difficulties in the population is vital for developing appropriate treatments and strategies to help with this. this will be the first study to investigate rates of, and factors contributing to, perceived cognitive difficulties in a large population exposed to multiple stressors and is important for the population of canterbury, and populations affected by natural and man-made disasters worldwide. four hundred and sixty people who were exposed to the canterbury earthquake sequence will be recruited from the christchurch health and development study (chds). psychological, cognitive, functional and biological factors will be compared between those with the greatest levels of perceived cognitive difficulty and those with the lowest levels of difficulty. this will determine what factors relate most strongly to perceived cognitive difficulties, which will in turn be used to develop treatments for this population.


Eligibility criteria:
inclusion criteria: * cohort member of the christchurch health and development study (born in 1977) * exposed to the canterbury earthquake sequence * in the highest or lowest quartile with regards to score on the cognitive failures questionnaire exclusion criteria: * lifetime diagnosed psychotic disorder * previous moderate to severe head injury (\> 30 minutes loss of consciousness) * current pregnancy * intellectual disability (iq \< 80) * residing outside of canterbury

Keywords: trauma earthquake cognitive impairment
clinical outcomes of resective surgical treatment of peri-implantitis with or without implantoplasty

Conditions: Peri-Implantitis

Summary: the aims of the current study are 1) to assess the therapeutic resolution of the peri-implantitis after resective surgical treatment with or without implantoplasty procedure (no further radiographic bone loss, no erythema of the peri-implant mucosa, pd \<6mm), and 2) to evaluate the survival rate of the peri-implantitis treated dental implants.

the records of patients who underwent resective surgical treatment for peri-implantitis at the university of michigan graduate periodontics clinic will be examined and analyzed. patients who meet the inclusion/exclusion criteria will be contacted and invited to participate in the study to measure the following in a single visit: bleeding on probing, edema, redness of the peri-implant mucosa, and peri-implant probing pocket depth. additionally, patients will be asked to complete a survey during their study visit regarding their implant(s) and previous peri-implantitis.

Eligibility criteria:
inclusion criteria: 1. the patient is at least 18 years of age, 2. was initially diagnosed with peri-implantitis at ≥1 implant (peri-implant probing depth (ppd) ≥ 6 mm together with bleeding and/or suppuration on probing (bop/sop) and bone loss progression over physiological bone remodeling radiologically assessed or marginal bone loss ≥ 3 mm radiologically assessed in case of absence of baseline radiographs), 3. had received treatment for peri-implantitis at least 1 year ago at the graduate clinic of periodontics at university of michigan, and 4. documentation from ≥ 1 year of clinical and radiological follow- up is available from u of m patients records. exclusion criteria: 1. has received or is currently receiving radiotherapy, 2. are currently pregnant, unsure of their pregnancy status, or are lactating (as reported by the patient), 3. has health condition(s) or takes medication(s) that are known to affect soft tissue or bone (e.g., phenytoin) 4. received any kind of bone graft during the treatment of the peri-implantitis
a study of tazemetostat in participants with relapsed or refractory b-cell non-hodgkin's lymphoma

Conditions: Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Summary: this is a multicenter, single-arm, open-label, phase 1 study to assess the tolerability, safety, pharmacokinetics, and preliminary anti-tumor activity of tazemetostat in participants with relapsed or refractory b-cell non-hodgkin's lymphoma (nhl).


Eligibility criteria:
inclusion criteria: * participants with histological diagnosis of b-cell non-hodgkin's lymphoma * participant who has measurable disease * participant who had previous therapy with systemic chemotherapy and/or antibody therapy * participant who had progressive disease (pd) or did not have a response (complete response \[cr\] or partial response \[pr\]) in previous systemic therapy, or relapsed or progressed after previous systemic therapy * participant with eastern cooperative oncology group (ecog) performance status of 0 to 1 * participant with life expectancy of ≥3 months from starting study drug administration * participant with adequate renal, bone marrow, and liver function * participant with left ventricular ejection fraction (lvef) \> 50% * male and female participant ≥20 years of age at the time of informed consent * participant who has provided written consent to participate in the study exclusion criteria: * participant with prior exposure to ezh2 inhibitor * participant with a history or a presence of central nerves invasion * participant with allogeneic stem cell transplantation * participant with medical need for the continued use of potent or moderate inhibitors of cyp3a or p-gp, or potent or moderate inducer of cyp3a (including st. john's wort). * participant with significant cardiovascular impairment * participant with prolongation of corrected qt interval using fridericia's formula (qtcf) to \> 480 milliseconds (msec) * participant with venous thrombosis or pulmonary embolism within the last 3 months before starting study drug * participant with complications of hepatic cirrhosis, interstitial pneumonia, or pulmonary fibrosis * participant with active infection requiring systemic therapy * women of childbearing potential or man of impregnate potential who don't agree to use a medically effective method for contraception for periods from before informed consent to during the clinical study and 30 days later from last administration of study drug * woman who are pregnant or breastfeeding * participant who were deemed as inappropriate to participate in the study by the investigator or sub-investigator

Keywords: relapsed or refractory b-cell non-hodgkin's lymphoma tazemetostat japan e7438
pharmacotherapy and psychotherapy for mdd after remission on psychology and neuroimaging

Conditions: Depressive Disorder

Summary: the purpose of this study is to determine the level of residual symptoms and psychosocial factors affecting recovery of psychosocial functions in mdd patients who reach remission, and investigate the recovery process of psychosocial functions. the investigators suppose that even the patient is well-treated by drug,there are still many residual symptoms,and they also exist different degree of damage in the structure and functions of brain. cbt could help them obtain better recovery,especially in psychosocial functions.

objective:at present, clinical remission of depression is defined as a final hamd score of less than 7. however, in clinical practice, the psychosocial functions of patients who reach remission are far from complete recovery. the recovery of psychosocial functions lags behind the disappearance of symptoms.so,we aim to determine the level of residual symptoms and psychosocial factors affecting recovery of psychosocial functions in mdd patients who reach remission, and investigate the recovery process of psychosocial functions. method:200 mdd patients who met the inclusion criteria were randomly divided into cbt group and control group.all of subjects would complete the psychological assessment at 0,1st,2nd,6th and 12th months for cbt group and 0,2nd,12th months for control group.all participants would undergo magnetic resonance imaging at 0,2nd,12th months.the scanning sequence is 3d,resting-state,task-state and diffusion tensor imaging（dti）.during the magnetic resonance imaging（mri） scans, subjects performed the facial and gender recognition tasks with three different facial stimuli(positive/neutral/negative).

Eligibility criteria:
inclusion criteria: * clinical diagnosis of major depressive disorder (mdd) * hamilton rating scale for depression(hamd) less than 7 exclusion criteria: * bipolar disorder * substance dependence * neurological disorder or other mental disorder * severe body disease

Keywords: depression remission pharmacotherapy psychotherapy neuroimaging psychology
ppar - combination with metformin

Conditions: Diabetes Mellitus

Summary: a phase 3, randomized, double-blind, placebo controlled, multicenter trial to evaluate the safety and efficacy of bms-298585 in combination with metformin therapy in subjects with type 2 diabetes who have inadequate glycemic control on metformin therapy alone


Eligibility criteria:
inclusion criteria: * type 2 diabetes * hba1c \> - 7.0% and \< - 10.0 % * mean serum triglyceride \< - 600 mg/dl * body mass index \< - 41 kg/m2 * fasting c-peptide \> - 1.0 ng/ml exclusion criteria: * history of myocardial infarction (mi) * coronary angioplasty or bypass graft(s) * valvular disease or repair * unstable angina pectoris * transient ischemic attack (tia), cerebrovascular attack, or cerebrovascular accident (cva) within 6 months * congestive heart failure nyha class iii and iv * uncontrolled hypertension * history of renal disease, peripheral vascular disease (pvd), pulmonary disease, gastrointestinal disease, active liver disease or endocrine disease

Keywords: metabolics diabetes new onset
coagulopathy in cardiac surgery

Conditions: Coagulopathy, Cardiac Surgery, Cardiopulmonary Bypass

Summary: coagulopathy in cardiac surgery; a quaternary-care academic center experience objectives: primary: to determine incidence of coagulopathy after cardiac surgery in thai people to determine incidence of resternotomy for stop bleeding, morbidity and mortality secondary: to identify risk factors which associated with non-red cell transfusion and coagulopathy study decide: retrospective chart review

data to be collected: age\*, gender\* body weight, height, body mass index\* underlying disease: dm, renal disease\*, liver disease\* pre-op. antiplatelet or anticoagulant\* pre-op coagulogram and platelet count\* emergency or elective surgery resternotomy or not\* intraoperative blood component intraoperative factor concentration dose and timing of antifibrinolytic administration\* cpb time\* postoperative body temperature\* \*possible risk factors for non-red cell transfusion statistic: to assess the relationship between risk factors and non-red cell transfusion a univariate analysis was performed using an unpaired t-test and a chi-square test. for higher accuracy regarding the impact of single risk factors, a multiple logistic regression analysis was also performed.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * schedule to cardiac surgery under cardiopulmonary bypass exclusion criteria: * schedule for aortic surgery or complex congenital cardiac surgery * using ecmo before surgery * incomplete anesthetic record
ensite precision observational study

Conditions: Cardiac Arrhythmia

Summary: this document is a clinical investigation plan (cip) for the ensite precision observational study. this clinical study is intended to quantify and characterize the usage of the ensite precision™ cardiac mapping system (software version 2.0.1 or higher) in a real-world environment. this study will be conducted in patients who are indicated for a cardiac electrophysiological (ep) mapping and radio frequency ablation procedure using a three-dimensional system.

the ensite precision™ cardiac mapping system is a newly developed system that introduces features such as delayed enhancement magnetic resonance imaging (de-mri) image integration, lesion marking automaticity, automatic mapping, and workflow flexibility to aid in the success of complex ablation procedures. utilization of this system in the treatment of complex ablation procedures and its impact on patient outcomes is not well characterized. this clinical study is designed to collect a broad range of usage scenarios, therefore this clinical study has limited patient selection criteria and data collection is focused on ensite precision™ cardiac mapping system usage and patient outcomes. the data collected from the procedure (performed per instructions for use (ifu) and per standard practice of the physician) as well as the 12 month follow up period enables the sponsor to review the system's standard practice usage. this information will be added to the current knowledge and understanding of treatment options for patients with arrhythmias, which can assist the sponsor to provide future recommendations for best practices to improve patient outcomes.

Eligibility criteria:
inclusion criteria: * indicated for a cardiac electrophysiology mapping and radiofrequency ablation procedure using a 3-dimensional mapping system per instructions for use * over 18 years of age * able to provide informed consent for study participation and willing and able to comply with the protocol described evaluations and follow up schedule exclusion criteria: * patients who are only presenting with: * atrioventricular nodal reentrant tachycardia (avnrt) * atrioventricular reentrant tachycardia (avrt) * planned cryoablation procedure * implanted with a neurostimulator * contraindication to anticoagulation * known presence of cardiac thrombus * recent (\<3 months) myocardial infarction or unstable angina or coronary artery by-pass * currently enrolled in a clinical study/investigation evaluating another device or drug that would confound the results of this study * pregnant or nursing * individuals whose willingness to volunteer in a study, in the judgement of investigator or public authorities, could be unduly influenced by lack of or loss of the autonomy due to immaturity, or mental disability, or adverse personal circumstances, or hierarchical influence

Keywords: atrial fibrillation atrial flutter supraventricular tachycardia ventricular tachycardia premature ventricular contractions cardiac mapping system
contagious itch, disgust and empathy in patients and medical staff

Conditions: Contagious Itch

Summary: this study is to assess the relationship between ci, disgust and empathy in medical staff treating patients with scabies, to differentiate the impact of visual and verbal stimuli contributing to ci and to assess information about ci, disgust and empathy in a family infested with scabies.

itch is the commonest skin-related symptom, defined as a bodily sensation provoking the urge to scratch. the induction of itch and scratching by mere (audio-) visual stimuli such as pictures of insects on skin or video clips showing individuals scratching themselves, indicates that itch can be perceived in the absence of a pruritogenic somatosensory stimulus. this phenomenon is referred to as "contagious itch" (ci). ci may play a special role in the content of scabies both for the affected patients as well as the treating staff: it is a very common phenomenon that family members who are not infested by scabies themselves experience itch when watching their infested relatives scratching. the same is very frequently expressed by health care professionals being confronted with scabies patients. two further important factors may be involved in the context of ci: disgust and empathy. empathy is defined as a psychological concept that enables individuals to understand and share emotions of others. disgust is an emotional response of revulsion to potentially contagious and/or harmful objects or subjects. this study is to assess the relationship between ci, disgust and empathy in medical staff treating patients with scabies, to differentiate the impact of visual and verbal stimuli contributing to ci and to assess information about ci, disgust and empathy in a family infested with scabies.

Eligibility criteria:
inclusion criteria: * members of families (aged \>7 years) hospitalized in the department of dermatology with scabies * staff (physicians, nurses, nurse aids aged \>16 years) involved in the treatment of these families * infestation of scabies in individual family members confirmed by two leading dermatologists of the university hospital basel by dermoscopy and/or skin scrapings. exclusion criteria: -

Keywords: itch scabies ectoparasites post-scabetic itch disgust empathy
study of sim0500 alone in participants with relapsed or refractory multiple myeloma

Conditions: Relapsed or Refractory Multiple Myeloma

Summary: this is an open-label, multicenter phase 1 clinical trial to evaluate the safety and tolerability, efficacy, and pharmacokinetics of sim0500 in adult participants with relapsed or refractory multiple myeloma(rrmm). the trial is consisted of two parts, part 1 (dose escalation) and part 2 (dose optimization). in both parts, sim0500 will be administered until disease progression, intolerable toxicity, withdraw of consent or end of trial.


Eligibility criteria:
inclusion criteria: 1. voluntary participation and signature of informed consent form. 2. ≥18 years of age. 3. have documented diagnosis of relapsed or refractory multiple myeloma according to criteria for response to multiple myeloma treatment(imwg)diagnostic criteria who have failed all established standard of care. 4. life expectancy ≥12 weeks. 5. eastern cooperative oncology group (ecog) score of 0 or 1. 6. adequate hematologic, hepatic, and renal function. exclusion criteria: 1. toxicities from previous anticancer therapies should have resolved to baseline levels or to grade 1 or less except for alopecia or peripheral neuropathy. 2. active hepatitis b (hbsag positive and hbv dna ≥ 1×104 copies/ml or ≥ 2,000 international unit \[iu\]/ml) or hepatitis c (hcv antibody positive and hcv rna ≥ uln) infection; participant with hbsag positive or detective hbv-dna at screening should receive antiviral treatment as per local practice during the trial. 3. known human immunodeficiency virus (hiv) infection or acquired immunodeficiency syndrome (aids). 4. participant is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial. 5. active known or suspected autoimmune disease. participants with vitiligo, residual hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment or conditions not expected to recur in the absence of an external trigger, type 1 diabetes mellitus (blood glucose can be controlled by insulin therapy) can be included. 6. current or previous other malignancy within 3 years of study entry, except basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix or breast. 7. known active central nervous system (cns) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma. 8. participants with known active infection within 14 days prior to the first sim0500.
standard treatment for non-specific low back pain combined with multimodal osteopathy treatment on pain intensity and functional capacity

Conditions: Low Back Pain

Summary: background: low back pain is one of the most common musculoskeletal health problem with the highest prevalence in the adult population; globally, it represents a relevant cause of medical, social and economic burden. the aim of the proposed study is to determine the effect of a standard treatment for non-specific low back (cnslbp) combined with multimodal osteopathy treatment on pain intensity and functional capacity. methods: this will be a blind randomized clinical trial, with 44 patients with cnslbp, randomly assigned into two groups: experimental group (eg) treated with therapeutic exercises and multimodal osteopathy treatment (n=22) and control group (cg) treated with therapeutic exercises (n=22). participants will receive treatment twice a week (total of 16 sessions). the primary outcome is pain, measured by numeric rating scale (nrs: score 0-11 points). secondary outcomes are: patient-specific functional scale (scored from 0 to 30), oswestry disability questionnaire (odq), finger-to-floor distance test (ffd). participants will be evaluated pre- and post-treatment and after 1 and 3 months (follow-up). results: analysis will be by intention to treat using linear mixed models. comparisons between groups before and after treatment will demonstrate whether osteopathy treatment exerts a supplementary effect on pain and functional capacity in patients with cnslbp. the data will be published after the study is completed. the study will support the practice of evidence-based physical therapy for individuals with cnslbp.


Eligibility criteria:
inclusion criteria: * individuals within the age range of 18-70 years; * chronic low back pain in the region between the 12th rib and the gluteal fold, with a minimum duration of 6 weeks with or without referral of pain in the lower limbs; * no specific cause detectable, such as infection, neoplasia, metastasis, osteoporosis, rheumatoid arthritis, fracture, inflammatory process or radicular syndrome. * baseline pain: minimum intensity score of 3 out of 10 (0 = no pain, 10 = most intense pain) considered and verified by the numerical pain rating scale (nprs). exclusion criteria: * previous history of spinal disorders (local trauma, cauda equina syndrome, spinal canal stenosis, congenital abnormalities tumor); * inflammatory or infectious diseases (rheumatoid arthritis, fibromyalgia and vertebral osteomyelitis); * previous lumbar spine surgery; * pregnant women; * regular opioid analgesics (≥2 times per week) or opioid patches; * receiving disability benefits for back pain or even for another health reason; * previous injections for back pain, such as facet joint blocks, nerve root or epidural steroid injection in the previous year; * having undergone physical therapy, massage, acupuncture or any other therapeutic intervention for back pain in the previous two weeks; * osteopathy techniques that are not used as a treatment for low back pain; * neuropathic pain tested with laségue and valsalva clinical tests.
colorectal cancer associated host and microbiome study

Conditions: Colorectal Neoplasms

Summary: recruit of healthy, precancer and colorectal cancer patients and record necessary information of demographic and also other messages. all the volunteers were asked to provide samples including stool, blood, urine and tissues. this protocol is performed with the permission of the ethics committee and all the participants were provided with informed consent.

healthy subjects, precancer patients identified by colonoscopy or colonoscopy history and colorectal cancer patients identified by two independent pathologists will be enrolled. the demographic message including age, weight, height, drug history, family history of all participants will be recorded. blood, stool and urine samples will be collected of all subjects. tumor and adjacent tissue samples of colorectal cancer and precancer patients were collected, as well as normal tissue of healthy subjects.

Eligibility criteria:
inclusion criteria 1. individuals who were clear and signed the informed consent. 2. male and female. 3. age \>18 exclusion criteria: 1. any one who can not provide accurate information. 2. any one who denies the study. 3. younger than 18.